Teel Ascends to Arvinas CEO Post Amid Clinical Pipeline Expansion

Arvinas, Inc. (Nasdaq: ARVN) has elevated Randy Teel, Ph.D., to the position of President and Chief Executive Officer, effective February 12, 2026. The appointment marks a significant leadership transition at the clinical-stage biotechnology company pioneering targeted protein degradation therapies. Teel assumes the role as the company enters a critical phase of clinical development, having recently achieved its first successful pivotal trial results for a PROTAC degrader—a landmark achievement in the field.

The decision reflects the company’s strategic focus on advancing its differentiated clinical pipeline while building on the foundation established over the past decade. Teel, who previously served as Chief Business Officer, brings both internal expertise and a deep institutional knowledge of Arvinas’ scientific and operational infrastructure. His elevation signals the board’s confidence in his ability to navigate the company through its next growth phase while maintaining momentum in drug development.

Strategic Leadership Transition

Teel succeeds John Houston, Ph.D., who is retiring as President, CEO, and Board Chair after nine years leading the company. During his tenure, Houston advanced Arvinas through major milestones including the 2018 initial public offering, securing over $2 billion in funding through private investments and strategic partnerships, and progressing multiple investigational programs into clinical development.

Houston will remain engaged with the company through a consulting arrangement, providing strategic guidance as Arvinas approaches several anticipated data readouts. Briggs Morrison, M.D., has been elected as the new Board Chair, taking over governance responsibilities effective immediately.

“After a comprehensive search, the board is confident that Teel is the ideal leader to accelerate Arvinas’ mission,” said Morrison in a statement. “His strategic vision, combined with his proven ability to refocus company strategy around our most promising clinical candidates and his deep understanding of the biotechnology industry, uniquely positions him to lead the organization forward.”

PROTAC Platform Leadership and Clinical Milestones

Teel joined Arvinas in 2018 and has been instrumental in the company’s development trajectory, playing a critical role in its initial public offering and transition to a public clinical-stage company. Over his six-year tenure at Arvinas, he has led corporate strategy, business development, investor relations, and communications initiatives. Prior to joining Arvinas, Teel spent approximately 15 years in senior strategic roles, including serving as Vice President and Head of Strategy at Alexion Pharmaceuticals, where he shaped commercial and lifecycle management strategies for pharmaceutical candidates.

His earlier experience also includes consulting engagements at McKinsey & Company, where he advised biopharmaceutical clients on commercial, medical, and development strategy. He holds a B.Sc. in Biology from Gonzaga University and a Ph.D. in Immunobiology from Yale University, providing him with both industry expertise and scientific rigor.

Building on Nine Years of Clinical Achievement

Under the company’s PROTAC platform, Arvinas is progressing multiple investigational drugs toward clinical and commercial milestones. Current programs include ARV-102 for neurodegenerative disorders, ARV-393 for relapsed/refractory non-Hodgkin Lymphoma, ARV-806 for KRAS G12D-mutated cancers including pancreatic and colorectal cancers, and vepdegestrant for estrogen receptor-positive breast cancer.

The company has established itself as a leader in targeted protein degradation, successfully demonstrating central nervous system pharmacodynamic activity for an orally administered PROTAC—a significant achievement indicating potential for neurodegenerative applications. These accomplishments have positioned Arvinas to advance into later-stage development phases with a robust pipeline and experienced leadership team.

“I’m honored to lead Arvinas at this pivotal moment,” said Teel. “Following our first successful pivotal trial of a PROTAC degrader, we are directing our attention to our earlier-stage clinical programs and their potential to transform treatment approaches for patients with serious diseases. The team has built the industry’s leading PROTAC platform, and I look forward to continuing this work as we approach critical clinical milestones later this year.”